Ask AI
ProCE Banner Activity

Prospettive globali sulla diagnosi e sul trattamento della trombocitemia essenziale e della policitemia vera 

Clinical Thought

In questo breve commento, esperti internazionali discutono temi di attualità relativi alla diagnosi e al trattamento della trombocitemia essenziale (TE) e della policitemia vera (PV). 

Released: September 15, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme, LLC

Target Audience

This activity is intended for hematologists and other healthcare professionals caring for patients with essential thrombocythemia and polycythemia vera.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify underlying MPNs such as ET and PV in patients presenting with thrombotic events that are otherwise unexplained

  • Diagnose patients with ET and PV, including bone marrow biopsies and assessment of risk of thrombotic events

  • Determine prognoses for individual patients with ET and PV using prognostic scoring system and identification of immune biomarkers

  • Engage patients with ET and PV in shared-decision making to better align treatment with both best practices and patient preferences on risks and benefits

  • Prepare clinical practice to incorporate new second-line agents for ET and PV upon approval

Financial Disclosures

Primary Author

Ciro Rinaldi MD, PhD, has no relevant financial relationships to disclose.

Alessandro M. Vannucchi, MD: consultant/advisor/speaker: AbbVie, AOP Health, GSK, Italfarmaco, Menarini Stemline, Novartis; researcher (paid to institution): Ionctura.